Transcript Slide 1

Deeley Research Centre, BC Cancer Agency
Dr. Nelson received training at the University of California at Berkeley (Ph.D.) and
Fred Hutchinson Cancer Research Center (postdoc), and in 2003 became founding
Director of the Deeley Research Centre. His laboratory is interested in the
development of immune-based therapies for cancer. Areas of focus include:
defining the effects of standard treatments on the immune response to cancer;
understanding how cytokine signals modulate the anti-tumour activity of tumourinfiltrating T cells; and using genomic approaches to identify novel tumour mutations
that can serve as target antigens for immunotherapy.
Brad H. Nelson, Ph.D.
Director & Senior Scientist, DRC
Associate Professor, UBC
Adjunct Associate Professor, UVIC
Dr. Watson began his medical training at the University of Cambridge and St.
Thomas’ Hospital and completed speciality training in Pathology at the University of
Manitoba, where he served on faculty from 1993. He joined the BC Cancer Agency
in 2005 to become the Director of the Tumour Tissue Repository and more recently
Chief Physician of the Vancouver Island Cancer Centre in 2009. Dr. Watson has a
long-standing interest in the molecular pathology and biomarkers of breast cancer.
His laboratory has pioneered work on S100A7 and its role in breast cancer
progression.
Peter H. Watson, M.D.
Director, Tumour Tissue Repository
Physician-in-Chief, VIC
Adjunct Professor, UBC and UVIC
Dr. Lum obtained his Ph.D. from the University of Ottawa and pursued a postdoctoral fellowship at the University of Pennsylvania with Craig Thompson. His
research program is interested in understanding how cellular metabolism regulates
tumorigenesis. He is studying how autophagy promotes tumour cell survival and
studying whether these pathways can be used as novel targets for T cell therapy.
Julian J. Lum, Ph.D.
Research Scientist, DRC
Adjunct Assistant Professor - UVIC
Dr. Webb completed his graduate training at the University of British Columbia and
spent several years working in industry before becoming a faculty member at the
University of Ottawa. Following this, he returned to industry and developed an
interest in vaccines for human malignancies. Dr. Webb joined the Deeley Research
Centre as the T cell Projects Leader continuing his work in cancer immunotherapy.
In addition, Dr. Webb has been studying new vaccine strategies to induce T cellmediated immune responses.
John Webb, Ph.D.
Leader, T Cell Projects
Adjunct Associate Professor - UVIC
LEGEND
UBC: University of British Columbia
UVIC: University of Victoria
DRC: Deeley Research Centre
VIC: Vancouver Island Centre